icon-folder.gif   Conference Reports for NATAP  
 
  HEPDART 2015: Frontiers in
Drug Development for Viral Hepatitis
December 6-10 2015
Wailea, HI
Back grey_arrow_rt.gif
 
 
 
PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR)
 
 
  Reported by Jules Levin
HepDART, Wailea, HI. Dec 6-10, 2015
 
Ernest Asante-Appiah, Ira Jacobsen, Peggy Wong, Todd Black, Anita Howe, Janice Wahl, Michael N. Robertson, Bach-Yen Nguyen, Melissa Shaughnessy, Peggy Hwang, Eliav Barr and Daria Hazuda
 
AASLD: Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks - (11/23/15)
 
AASLD: Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF - (11/16/15)
 

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif